11th Annual Biosimilars & Biologics Summit

11th Annual Biosimilars & Biologics Summit

Seaport Hotel & World Trade Center (and Livestream)
Speaking Engagement

2020 marks ten years since the passage of the Biologics Price Competition and Innovation Act. The US biosimilars market continues to maintain its momentum, but important questions and barriers remain. 

The ACI’s 11th Annual Summit on Biosimilars & Innovator Biologics is the industry’s foremost event directed to the legal, regulatory and commercial aspects of the biosimilars marketplace. The speaking faculty consists of top innovator and biosimilar makers, government representatives and leading law firms who will discuss critical industry developments and provide skilled insights into the design and execution of successful biosimilars strategies.

WilmerHale Partner Kevin Prussia will speak on the panel “Key Litigations and Decisions at the Federal Circuit, the District Courts and the PTAB Affecting the Biologics Landscape” alongside Venable Partner Christopher Borello, Paul Hastings Partner Eric Dittmann, Biocon Biologics Chief IP Counsel Arshad Jamil and Honigman LLP Partner Gregory Morris.

A livestream option for this event will be available. 

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.